Nuvation Bio Earnings Call: Key Takeaways
Nuvation Bio reported strong Iptrosi growth despite a 15% market-wide decline in ROS1 TKI starts, while advancing its IDH1 mutant glioma program toward 2027 data readouts.
- Call
- Nov 4, 2026, 4:30 PM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nuvation Bio Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts
Nuvation Bio reported strong Iptrosi growth despite a 15% market-wide decline in ROS1 TKI starts, while advancing its IDH1 mutant glioma program toward 2027 data readouts.
Nuvation Bio reported third quarter 2026 financial results, highlighted by $45.0 million in total revenue and $27.5 million in net product revenue for its ROS1 inhibitor IBTROZI. The company ended the quarter with $663.4 million in cash and marketable securities while achieving market leadership in new patient starts for ROS1+ NSCLC.
“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data.”
David Hung, M.D., Founder, President, and Chief Executive Officer
“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI’s durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy.”
David Hung, M.D., Founder, President, and Chief Executive Officer
Nuvation Bio Inc. reported financial results for the third quarter of 2026, highlighting continued progress in its clinical oncology programs. The company maintained a robust cash position to support operations through 2028, while reporting a net loss driven by ongoing research and development expenses.